Lucid Health Consulting - Experience Matters.

What Lucid Health Consulting - Experience Matters. does

Lucid Health Consulting is an Australian private healthcare consultancy founded in 2015 by George Papadopoulos, Michael Aristides, and Steve Crowley, headquartered in North Sydney with an additional Melbourne office. The firm provides specialized advisory services across market access and pricing strategy, reimbursement submissions to Australian health technology assessment bodies (PBAC, MSAC, LSDP, Prostheses List), regulatory affairs and TGA interactions, health economic modeling and budget impact analyses, statistical analyses including network and indirect meta-analyses, and product sponsorship for overseas companies without an Australian legal entity. Its clients are pharmaceutical, biotechnology, medical device, and medical technology companies entering or expanding in Australia, New Zealand, and the Asia-Pacific region, including enterprise pharma (Takeda, Baxalta, Janssen-Cilag) and clinical-stage biotechs (Tryptamine Therapeutics).

The firm has no proprietary software platform; its core technology stack consists of methodology-driven health economic and statistical analyses delivered by a team of ~11 senior consultants and directors, supplemented by an integration with MAOSS for Australian reimbursement and PBS data and a public PBS Price Calculator tool. The team carries 80+ years of combined experience in Australian HTA, with founders having prior senior roles at global pharma (Pharmacia, J&J, Schering-Plough, Merck), the Australian Federal Health Department, and IMS Health. Revenue is generated through project-based, quote-driven professional services engagements, with strategic partnerships extending capability reach across Asia Pacific (Vista Health, 2023) and embedding reimbursement data workflows (MAOSS, 2020). Lucid Health Consulting has been publicly identified as an IQVIA business.

Name

Lucid Health Consulting - Experience Matters.

Legal name

Lucid Health Consulting

Website

https://lucidhealthcon.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Lucid Health Consulting is an Australian healthcare consultancy that advises pharmaceutical, biotech, medical device, and medical technology companies on market access, health economics, pricing and reimbursement, and regulatory affairs across Australia, New Zealand, and Asia Pacific.

Ownership category

akta.pro rank

Headquarters

HQ city

North Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Strategic Consulting Services: Professional consulting services in market access, health economics, pricing & reimbursement, regulatory affairs, and statistical analyses for pharmaceutical, biotech, medical device, and medical technology companies entering Australian and Asia-Pacific markets. Revenue generated through project-based engagements and ongoing advisory relationships.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Lucid Health Consulting provides specialized consulting services in market access, health economics, pricing and reimbursement, and regulatory affairs to pharmaceutical, biotechnology, medical device, and medical technology companies seeking entry or expansion in Australia, New Zealand, and the Asia-Pacific region. Service delivery spans reimbursement submissions to PBAC/MSAC, TGA regulatory affairs, health economic modelling and evaluations, statistical analyses, and acting as local product sponsor via a TGA Client ID for companies without an Australian legal entity.

Product overview

Lucid Health Consulting is an IQVIA business providing integrated consultancy services for market access, health economics, pricing, reimbursement, and regulatory affairs across Australia, New Zealand, and the Asia-Pacific. Their core service portfolio includes six interconnected offerings: Market Access and Pricing Strategy, Reimbursement Submissions (PBAC, MSAC, LSDP, PL), Regulatory Affairs/Quality/Advocacy, Economic Modelling and Evaluations, Statistical Analyses/Research/Market Intelligence, and Product Sponsorship and Commercialisation. The company also offers a PBS Price Calculator as a free online resource tool. With over 80 years of combined team experience and offices in Melbourne and Sydney, they support pharmaceutical, biotech, medical device, and technology companies in navigating the Australian healthcare market from early development through commercial launch.

Differentiator

Problem solved

Functional benefit

Products and services

• Market Access and Pricing Strategy Strategic consultancy helping pharmaceutical, biotech, medical device and technology companies plan and optimize market entry, pricing strategy, and market access in Australia and the Asia-Pacific region.
• Reimbursement Submissions (PBAC, MSAC, LSDP, PL) Expert preparation and submission of reimbursement applications to Australian health technology assessment bodies including the Pharmaceutical Benefits Advisory Committee (PBAC), Medical Services Advisory Committee (MSAC), Life Saving Drugs Program (LSDP), and Prostheses List (PL).
• Regulatory Affairs, Quality and Advocacy Regulatory strategy, compliance, and advocacy services including TGA interactions, product classification, regulatory feasibility assessments, gap analysis, pre-submission meetings, submission roadmaps, and lifecycle management for pharmaceuticals, medical devices, biotech products, and technologies in Australia.
• Economic Modelling and Evaluations Health economic modelling including cost utility analyses, cost effectiveness analyses, cost benefit analyses, cost minimisation analyses, budget impact models, and global model adaptations for Australia and international markets.
• Statistical Analyses, Research, and Market Intelligence Statistical and research services including indirect and network meta-analyses, analyses of individual patient data, patient preference studies (discrete choice design and analyses, willingness to pay studies), and market intelligence to support regulatory, pricing and reimbursement strategies.
• Product Sponsorship and Commercialisation Product sponsorship acting as local sponsor with the Therapeutic Goods Administration (TGA) for companies without an Australian legal entity, including ARTG applications, ongoing sponsorship maintenance, and regulatory compliance for pharmaceuticals, medical devices, technologies, and biotech products.

Quantifiable outcome

• Successful PBAC reimbursement submissions for complex indications including first-time positive recommendations
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Vista HealthcoreStrategic or Co-development Partner · 14 September 2023Strategic partnership with Vista Health (headquartered in Singapore) to deliver comprehensive health economics, HTA, pricing & reimbursement, market access, and regulatory affairs advisory services across the Asia Pacific region. The partnership enables both companies to offer seamless and holistic advisory experiences across key regional markets, combining Lucid's deep Australian expertise with Vista's broader Asia-Pacific network.
• MAOSSsupportingTechnology or Integration · 1 October 2020Strategic partnership with MAOSS (Market Access Operations Support System), a unique market access platform providing Australian reimbursement data. The partnership enhances Lucid's service offering with efficient data gathering and communication capabilities, including PBS item search, historical utilization data, pricing analysis, and Public Summary Document access for HTA submissions.
• Skyward AnalyticssupportingStrategic or Co-development PartnerResearch collaboration partnership with Skyward Analytics (Singapore) for joint abstract submissions and poster presentations at international conferences including ISPOR Europe 2025 (14 abstracts accepted) and ISPOR 2021-2023. Collaboration spans health economic modeling and budget impact analyses.
• MedTechnique ConsultingsupportingStrategic or Co-development PartnerOngoing collaboration with MedTechnique Consulting (directed by Sarah Griffin) for joint webinar hosting (Annual Drugs & Devices Australia Reimbursement Update series), conference sessions, and project engagements. Both firms specialize in medical device reimbursement strategy.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Global CRO with dedicated market access and HEOR capabilities (including former PRA Health Sciences teams). Competes for APAC pharma market access work as part of broader clinical and commercialization portfolio.
• Parexel International: Global CRO with integrated market access and HTA consulting via its Access Consulting group. Competes for the same pharma/biotech market access engagements but as part of a much larger clinical research portfolio.
• IQVIA: Global clinical research, commercial insights, and healthcare intelligence leader that has publicly absorbed Lucid as 'an IQVIA business.' Owns overlapping HEOR/HTA capabilities and is the parent-affiliate context in which Lucid now operates.

Direct peers

• Putnam Associates: Boutique strategy consulting firm focused on biopharma commercial strategy, pricing, and market access. Competes for similar pharma/biotech pricing and market access advisory mandates, particularly in oncology and rare disease.
• Certara: Regulatory science and market access consultancy with proprietary modelling software. Competes directly on PBAC/MSAC economic modelling, HTA submissions, and global regulatory strategy work for the same pharma/biotech client base.
• Evidera (PPD/Thermo Fisher): Specialized HEOR, HTA, and real-world evidence consultancy now part of Thermo Fisher's PPD. Closest competitor on PBAC/MSAC submissions, value communications, and global market access strategy for pharma/biotech.
• Crystallise: Specialist HEOR and systematic review consultancy serving pharma clients globally. Comparable boutique model focused on economic modelling, HTA submissions, and evidence synthesis for the same therapeutic areas.
• Costello Medical: Specialist HEOR, HTA, and medical communications consultancy serving pharma and biotech globally. Directly comparable specialty consulting model, with overlapping service lines (economic modelling, HTA submissions, real-world evidence) and similar project-based delivery.

Regional players

• Prospection: Australia-based health data analytics and real-world evidence firm. Regional peer with overlapping pharma/biotech client base in Australia and complementary capabilities in RWE and health data.

Others

• M-TAG (acquired by IMS Health/IQVIA): Australian HTA/health economics consultancy co-founded by Lucid's co-founder Michael Aristides in 1995, later acquired by IMS Health (now IQVIA). Closest historical precedent for Lucid's trajectory and capability set within the same geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lucid-health-consulting

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Health Consulting - Experience Matters.